- Home
- PRQR vs MIST Comparison
PRQR vs MIST Comparison
Compare PRQR & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRQR | MIST |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | Netherlands | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.5M | 176.3M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PRQR | MIST |
|---|---|---|
| Price | $1.50 | $1.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $7.25 | ★ $8.00 |
| AVG Volume (30 Days) | 566.6K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,915.14 |
| Revenue Next Year | $13.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $1.00 |
| 52 Week High | $3.10 | $3.06 |
Technical Indicators
Market Signals| Indicator | PRQR | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 26.80 |
| Support Level | $1.37 | $1.00 |
| Resistance Level | $1.58 | $2.30 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 53.45 | 4.40 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).